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Abstract Guanylyl cyclase C (GC-C), specifically expressed by
intestinal epithelial cells, is the receptor for the Escherichia coli
heat-stable enterotoxin that causes diarrhea. Tissue-specific
expression of GC-C is mediated by the intestinal transcriptional
regulator CDX2. This trans-activating protein regulates intes-
tine-specific expression by binding to a critical sequence in the
proximal promoter of GC-C. The precise nucleotide elements
mediating CDX2 binding to promoter elements remain unde-
fined. Several nuclear proteins form complexes with a DNA
probe containing the promoter element of GC-C mediating
CDX2 binding. The present study examined the nucleotide
requirements in the consensus binding site and flanking regions in
the cis element that mediates specific CDX2 binding to the
promoter of GC-C. These studies identified seven core base pairs
in the critical promoter element mediating tissue-specific
expression of GC-C that are required for CDX2 binding. In
addition, base pairs flanking this core sequence contribute to and
are required for CDX2 recognition. These studies describe the
precise nucleotide sequence within the GC-C promoter that
comprises the CDX2 binding site required for intestine-specific
expression. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Guanylyl cyclase C (GC-C) is the receptor for the Escheri-
chia coli heat-stable enterotoxin (STa), a principal cause of
travelers’ diarrhea, endemic diarrhea in underdeveloped coun-
tries, and neonatal diarrhea in agriculturally important animal
herds [1,2]. Binding of STa, or the endogenous ligands uro-
guanylin or guanylin [3^7], induces the catalytic domain of
GC-C to convert GTP to cGMP. Accumulation of cGMP
induces net secretion of £uid and electrolytes by enterocytes
resulting in diarrhea. In humans, GC-C is speci¢cally ex-
pressed only in di¡erentiated intestinal epithelial cells from
the duodenum to the rectum [8^11]. Detection of GC-C ex-
pression in extra-intestinal sites appears to be a sensitive and
speci¢c marker for colorectal cancer metastases [12].
Intestine-speci¢c expression of human GC-C is mediated by
a conserved region in the promoter from +118 to 3257 bp
relative to the start site of transcription [13,14]. DNA foot-
print analysis of the GC-C promoter identi¢ed a protected
region from 374 to 382 [14,15], containing a 5 bp consensus
binding sequence for the transcription factor CDX2 [14^16].
This region, FP1, is required for intestine-speci¢c expression
of a GC-C luciferase construct [15].
CDX2 is a member of the homeobox family of genes related
to the Drosophila melanogaster caudal gene. Homeobox pro-
teins are critical in processes underlying embryonic develop-
ment and have been implicated in the maintenance of adult
tissue architecture [17^20]. CDX2 plays a role in establishing
the di¡erentiated phenotype of intestinal epithelial cells [21^
23], and it regulates the transcription of enzymes important
for enterocyte function, including sucrase^isomaltase [16,24]
and lactase^phlorizin [25,26]. Expression of CDX2 and GC-
C is well correlated along the rostral^caudal and crypt-to-
villus axes [8,11,27,28].
Caudal family homeodomain proteins, including CDX2,
bind DNA in part by recognizing a speci¢c consensus se-
quence TTTAT/C [16,19,20,29]. Earlier studies demonstrated
that the base pair sequence in intestinal promoters, including
GC-C, mediating CDX2^DNA recognition includes the
TTTAT/C consensus sequence [14,16,25]. However, the pre-
cise nucleotide sequences required for speci¢c CDX2^DNA
interaction, including £anking stabilization sequences, remain
unde¢ned. Conversely, although CDX2 binds to the cis-pro-
moter element regulating intestine-speci¢c expression of GC-
C, other proteins also form complexes with this portion of the
GC-C promoter [13,14]. The present study examined the nu-
cleotide sequence in the consensus and £anking regions that
mediates recognition and stabilization of CDX2 binding to
the critical cis element of the GC-C promoter required for
intestine-speci¢c expression.
2. Materials and methods
2.1. Cell culture
Cell lines, obtained from American Type Culture Collection (Rock-
ville, MD, USA), were grown in a 50:50 mixture of Ham’s F12 me-
dium and Dulbecco’s modi¢cation of Eagle’s medium (DMEM/F12,
Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine
serum (BioWhittaker, Walkersville, MD, USA), 10 000 U/ml penicil-
lin, and 10 000 Wg/ml streptomycin (BioWhittaker). Cells were main-
tained at 37‡C in a humidi¢ed 5% CO2/95% air atmosphere.
2.2. Nuclear protein extraction
Nuclear extracts were prepared as previously described [30]. Nu-
clear protein concentration was determined by BCA protein assay
(Pierce, Rockford, IL, USA).
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2.3. Nuclear protein binding reaction
Binding reactions (20 Wl) contained 5.0 Wg of nuclear extract, 5.0
mM dithiothreitol, 1.0 Wg poly-dIWdC-poly-dIWdC (Amersham Pharma-
cia Biotech, Piscataway, NJ, USA), and 0.5% Nonidet P-40 (Sigma,
St. Louis, MO, USA) in binding bu¡er (4.0% glycerol, 150 mM NaCl,
10 mM Tris^HCl, pH 7.5, 2.5 mM MgCl2). Reactions were pre-in-
cubated at 37‡C for 30 min, radiolabeled probe (50 000^100 000 cpm)
and/or competitor (WM) added, then incubated for an additional 30
min at 37‡C. In supershift studies, 2.0 Wl of mouse CDX1 or CDX2
polyclonal antibody (P. Traber, University of Pennsylvania, Philadel-
phia, PA, USA) were added to reactions after the pre-incubation for
30 min before addition of probe.
2.4. Electrophoretic mobility shift assays (EMSA)
Binding reactions were loaded onto 0.75 mmU16 cm2 6.0% non-
denaturing polyacrylamide gels prepared using 30% 37.5:1 acrylami-
de:bisacrylamide (Bio-Rad, Hercules, CA, USA) and 0.5UTBE (45
mM Tris borate, 1.0 mM EDTA, pH 8.3, Eppendorf, Westbury, NY,
USA), pre-run in 0.5UTBE at 200 V until the current reached 9.0
mA, then electrophoresed at 35 mA in 0.5UTBE bu¡er for V30 min.
Some lanes contained free probe and dye only (4.0% glycerol, 0.02%
bromophenol blue, 25 mM Tris^HCl, pH 7.5). Gels were dried and
exposed to phosphor plates, developed on a PhosphorImager SI (Mo-
lecular Dynamics, Sunnyvale, CA, USA), and analyzed by Image-
Quant software (Molecular Dynamics).
2.5. Competitor synthesis
Double-stranded oligomers that served as the labeled probe for
competitive binding studies were synthesized by the Nucleic Acid
Facility, Kimmel Cancer Institute (Thomas Je¡erson University, Phil-
adelphia, PA, USA). Wild-type and DC4 probes (Fig. 1) were derived
from the GC-C promoter and included FP1 (bold). Wild-type oligo-
mer, with 9 bp £anking each side of FP1, was sequentially mutated
[16] to construct six 27 bp competitors (Fig. 1). Three competitors
were constructed as negative controls, containing 3 bp disruptions
within FP1 (Fig. 1). Nine 27 bp competitors were prepared with single
base pair changes in FP1 (Fig. 1). Three competitors were prepared
with 3P or 5P £anking CT repeats and a single base pair change in, or
truncated version of, FP1 (Fig. 1). Two shorter competitors were
prepared with CT repeats £anking FP1 or FP1 with TTT mutated
to GGG (Fig. 1). Complementary strands were annealed in bu¡er (10
mM Tris, pH 7.5, 50 mM NaCl, 1.0 mM EDTA) to a ¢nal concen-
tration of 1.0 WM on a Hybaid thermal cycler (Teddington, UK) by
incubation at 94‡C for 10 min then a 1‡C/min ramp to 26‡C, followed
by transfer to ice and storage at 4‡C. Alternatively, probes were an-
nealed by boiling in H2O for 5 min, then slowly cooled to room
temperature (V1‡C/min) and stored at 4‡C.
2.6. Probe labeling
Annealed oligomers (5.0 pmol) were end-labeled using 1 U of T4
polynucleotide kinase (PanveraTakara, Madison, WI, USA) and 2.0
Wl of 7000 mCi/mmol [Q-32P]ATP (ICN, Costa Mesa, CA, USA). Free
[Q-32P]ATP was removed using the Qiaquick Nucleotide Removal kit
(Qiagen, Valencia, CA, USA) or Micro Bio-Spin chromatography
columns (Bio-Rad). Probes were diluted in 10 mM Tris^HCl, pH
7.5, to 50 000^100 000 cpm/Wl.
2.7. Cloning of human CDX2
T84 cDNA was reverse-transcribed in a 20 Wl RT reaction contain-
ing 1.0 Wg of T84 total RNA, 0.5 Wg of oligo-dT (15-mer, Promega,
Madison, WI, USA), 10 mM Tris^HCl, pH 8.3, 50 mM KCl, 1.0 mM
dNTP, 20 U RNasin (Promega), and 5.0 U AMV-RT (Promega)
using a Hybaid thermal cycler with the following program: 48‡C
for 60 min, 94‡C for 5 min, 25‡C for 5 min. CDX2-speci¢c oligonu-
cleotide primers (HindIII, forward: 5P-TACTAAGCTTTGGTGA-
GGTCTGCTCCCG-3P ; XbaI, reverse: 5P-TAGTCTAGAAATTGCT-
CTGCCGCTGCAG-3P) [31], designed with 5P insertions of unique
restriction endonuclease sites (bold), were used to amplify human
CDX2 from T84 cDNA. PCR was performed using the high ¢delity
LA PCR Kit (PanveraTakara) in 50 Wl reactions containing 10 Wl of
T84 cDNA product, 1UGC bu¡er, 2.5 mM MgCl2, 0.5 mM dNTP,
10 pmol each of forward and reverse primers, and 2.5 U of TaKaRa
LA Taq DNA polymerase (PanveraTakara) using a Hybaid thermal
cycler with the following program: 94‡C for 60 min, 30 cycles (94‡C
for 30 s, 58‡C for 30 s, 72‡C for 2 min), 72‡C for 5 min, 25‡C for
5 min. Ampli¢ed DNA product was digested with HindIII and XbaI,
subcloned into the plasmid vector pRc/CMV (Invitrogen, Carlsbad,
CA, USA), and sequenced by the Nucleic Acid Facility, Kimmel
Cancer Institute (Thomas Je¡erson University, Philadelphia, PA,
USA).
2.8. In vitro protein expression
Human CDX2 protein was generated by the TNT Quick-Coupled
Kit (Promega) with linearized pRc/CMV human CDX2 as template.
3. Results and discussion
Nuclear extracts from T84 human colon cancer cells formed
several complexes with labeled WT, one of which contained
CDX2 (Fig. 2A,B) [15]. Binding of labeled WT to T84 cell
nuclear extracts was e¡ectively competed by unlabeled WT. In
contrast, unlabeled competitor in which the TTT of the con-
sensus CDX2 binding sequence (TTTAT) was converted to
GGG (GGGAT; GGG, Fig. 1) did not compete with labeled
WT (Fig. 2). The nucleotides in FP1 mediating CDX2 binding
were de¢ned by EMSA, examining competition for binding to
T84 nuclear extracts of labeled WT and unlabeled competitors
Fig. 1. Competitor sequences employed in competitive EMSA. For simplicity, the sense strand of the promoter was selected to describe the se-
quences and designate the orientations of the mutants, but all alterations represent appropriate changes in both strands.
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(Fig. 2). MUT1^6 competed with labeled WT (Fig. 2A); in
contrast, MUT8, with three substitutions in the consensus
CDX2 binding sequence, did not compete with labeled WT.
MUT9 also did not compete, whereas MUT7 partially com-
peted, with labeled WT (Fig. 2A).
These observations suggest that the consensus CDX2 rec-
ognition sequence mediates CDX2 binding to the FP1 region
of the GC-C promoter. The contribution of each of the nine
individual base pairs within FP1 to protein binding was sub-
sequently examined employing mutant constructs PRO1^9
containing single base pair substitutions (Fig. 1). Competitors
containing substitutions for bases comprising the consensus
CDX2 binding sequence (PRO3, PRO4, PRO5, PRO6,
PRO7) did not compete with labeled WT (Fig. 2B). Base pairs
in 3P positions 8 and 9 (PRO8, PRO9) also did not compete
for labeled WT (Fig. 2B). In contrast, mutants containing
substitutions within FP1, but 5P to the consensus CDX2 bind-
ing sequence, competed with labeled WT (PRO1 and PRO2;
Fig. 2B). These results support the suggestion that the con-
sensus CDX2 binding sequence and the two 3P base pairs
mediate association of CDX2 with WT, with little or no con-
tribution by the two 5P-most base pairs of FP1.
The contribution of nucleotides £anking the consensus site
was speci¢cally examined. Changing G to T at the second 5P
position (PRO2; Fig. 1) did not alter the e⁄cacy of competi-
tion with labeled WT for binding (Fig. 2B); this substitution
was employed in some constructs (DC1^3; Fig. 1). Similarly,
substituting wild-type £anking regions with dinucleotide re-
peating sequences (CT; DC4, Fig. 1) did not reduce the e⁄-
cacy of competition with labeled WT for binding (Fig. 3); this
substitution was employed in some constructs (DC1^5, Fig.
1). Removing all 5P base pairs preceding FP1 (DC1, Fig. 1)
did not diminish the e⁄cacy of the mutant competitor to
compete for binding (Fig. 3A,B). In contrast, removing all
3P base pairs following FP1 (DC2, Fig. 1) eliminated the abil-
ity of the mutant competitor to compete for binding (Fig.
3A,B). These data suggest that the presence of base pairs
£anking the 3P end of FP1 enhances stability of CDX2 bind-
ing to the GC-C promoter.
Although the 3P seven base pairs of FP1, TTTATAG, are
critical for CDX2 binding, the role of the two 5P base pairs
required clari¢cation. Removing the two 5P base pairs of the
FP1 from DC1 (DC3, Fig. 1) completely eliminated the ability
of that competitor to compete with labeled WT (Fig. 3A).
Thus, the presence of base pairs in the ¢rst and second posi-
tions at the 5P end of the FP1 is important, but their identity
is not critical, for CDX2 binding.
After identi¢cation of the individual sequence requirements
for CDX2 binding, the base pairs were incorporated into an
Fig. 2. Competitive EMSA of labeled WT and unlabeled MUT or PRO mutants. A: Nuclear extracts from T84 cells were combined with la-
beled WT in the absence (Ctl) or presence of a 200-fold excess of unlabeled mutant competitors. Binding reactions were electrophoresed and
analyzed as described in Section 2. B: Nuclear extracts from T84 cells were combined with labeled WT in the absence (Ctl) or presence of a
40-fold excess of unlabeled mutant competitors. Binding reactions were analyzed as in A. Data are representative of at least two experiments
for each condition. An asterisk represents the CDX2^probe complex.
Fig. 3. Competitive EMSA of labeled WT and unlabeled DC mu-
tants. A, B: T84 nuclear extracts were combined with labeled WT
in the absence (Ctl) or presence of a 40-fold excess of the indicated
competitors. Binding reactions were performed and analyzed as in
Fig. 2. Data are representative of at least two experiments for each
condition. All lanes shown in each panel are from the same gel;
phosphorimages of a given gel were spliced together for clarity.
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18 bp oligomer. The 18-mer possesses the nine core base pairs
of FP1, three additional base pairs on the 5P end to optimize
double-stranded DNA stability, and six additional base pairs
on the 3P end (DC4, Fig. 1) to both optimize oligomer stabil-
ity and to stabilize CDX2 binding. DC4 e¡ectively competed,
whereas DC4 with TTT mutated to GGG (DC5, Fig. 1B) did
not compete, for binding with labeled WT (Fig. 3B). The se-
quence requirements for binding of labeled DC4 to CDX2,
determined by competitive EMSA, were identical to those of
labeled WT with respect to the core nine base pairs within
FP1, employing intestinal cell nuclear extracts (Fig. 4A) or
TNT CDX2 (Fig. 4B). Similarly, the requirements of the 5P
and 3P sequences £anking FP1 for binding of CDX2 to la-
beled DC4 in intestinal cell nuclear extracts were con¢rmed
(compare Figs. 3 and 5).
The ability of DC4 to bind speci¢cally to CDX2 was exam-
ined employing nuclear extracts from T84 and Caco-2 human
colon cancer cells, HepG2 human hepatoma cells, HeLa ¢bro-
blasts, and TNT human CDX2 (Fig. 6). Extracts from T84
and Caco-2 cells, but not from HepG2 or HeLa cells, formed
a single speci¢c complex with labeled DC4, compared to la-
beled WT which formed speci¢c and non-speci¢c complexes in
intestinal and extra-intestinal cells (compare Figs. 2 and 3
with Figs. 4^6) [15]. The major complex formed between la-
beled DC4 and T84 or Caco-2 cells exhibited a mobility iden-
tical to that of the complex formed between DC4 and TNT
human CDX2 (Fig. 6). An antibody against CDX2 decreased
the mobility of the speci¢c complex formed between DC4 and
nuclear extracts from T84 or Caco-2 cells or TNT human
CDX2 (Fig. 6). In contrast, an antibody against a related
homeodomain transcription factor, CDX1, did not alter the
mobility of the intestine-speci¢c complex (Fig. 6). These data
demonstrate that DC4 contains a speci¢c binding site for
Fig. 4. Competitive EMSA of labeled WT or DC4 and unlabeled MUT or PRO mutants employing intestinal cell nuclear extracts or TNT
CDX2. A, B: TNT protein (A) or Caco-2 nuclear extracts (B) were incubated with labeled WT or labeled DC4 in the absence of (Ctl) or pres-
ence of a 250-fold excess of the indicated competitors. Binding reactions were performed and analyzed as in Fig. 2. Data are representative of
at least two experiments for each condition.
Fig. 5. Competitive EMSA of labeled DC4 and unlabeled DC mu-
tants. T84 nuclear extracts were incubated with labeled DC4 probe
in the absence (Ctl) or presence of a 200-fold excess of the indicated
competitors. Binding reactions were performed and analyzed as in
Fig. 2. Data are representative of at least two experiments for each
condition.
Fig. 6. Interaction of labeled DC4 with CDX2. Nuclear extracts
from the indicated cells or TNT protein were incubated with labeled
DC4 in the EMSA binding reaction. Binding reactions were electro-
phoresed and analyzed as in Section 2. Data are representative of at
least two experiments for each condition. A double asterisk repre-
sents the K CDX2+ CDX2+ probe complex.
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CDX2 alone that is su⁄cient for binding the transcription
factor.
Caudal family homeodomain proteins regulate processes
central to di¡erentiation and development during ontogeny
and the maintenance of di¡erentiated tissues in the adult
[16,19,20,29]. The data presented in this study are the ¢rst
to completely de¢ne the requirements of speci¢c base pairs
for recognition, and £anking DNA for stabilization, of the
direct interaction of CDX2 with a promoter mediating intes-
tine-speci¢c expression of a gene. In addition, they are the ¢rst
to de¢ne the nucleic acid probes required to examine the
speci¢c interaction of CDX2 and cis-promoter elements by
EMSA [15,16,25]. These data will be employed to further
examine the role of CDX2 in regulating the expression of
GC-C and other genes characteristic of di¡erentiated intesti-
nal epithelial cells.
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